Lakhani, N. J., McKean, W. B., Rivera, I. I. R., Giordano, A., Yap, T. A., Dowlati, A., Subbiah, V., Wang, J. S., Bhave, M. A., Thein, K. Z., Fang, J., Connor, E. F., Liu, L., Cremin, P., Makris, L., Tsao, L. B., Kopp, L. M., Cox, M. C., Kummar, S. (2025). A phase 1 study to evaluate the safety, pharmacokinetics, and efficacy of the first-in-class cyclin A/B RxL inhibitor CID-078, an orally bioavailable, cell-permeable macrocycle.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps3175